ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 5, 2017

9:00AM-11:00AM
Abstract Number: 811
The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis
Vasculitis Poster I: Large Vessel Vasculitis
9:00AM-11:00AM
Abstract Number: 72
The Presence of IgM Rheumatoid Factor Impede Immunodetection of Tnfa on Circulating Extracellular Vesicles Obtained from Rheumatoid Arthritis Patients
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling
9:00AM-11:00AM
Abstract Number: 288
The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages
Innate Immunity and Rheumatic Disease Poster I
9:00AM-11:00AM
Abstract Number: 273
The Risk Factors of Developing Adult T Cell Leukemia (ATL) in Human T Cell Leukemia Virus Type 1 (HTLV-1) Positive Patients with Rheumatoid Arthritis in Endemic Area, Japan; A Retrospective Cohort Study
Infection-related Rheumatic Disease Poster
9:00AM-11:00AM
Abstract Number: 393
The Role of Follicular Helper 17 T Cells in Glucose-6-Phosphate Isomerase Induced Arthritis
Rheumatoid Arthritis – Animal Models Poster I
9:00AM-11:00AM
Abstract Number: 506
The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules
9:00AM-11:00AM
Abstract Number: 453
The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
9:00AM-11:00AM
Abstract Number: 19
The Transcription Factor Specificity Protein 1 up-Regulates IL-21 Receptor Expression on B Cells in Rheumatoid Arthritis Leading to Altered Cytokine Production and Maturation
B Cell Biology and Targets in Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 271
The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Infection-related Rheumatic Disease Poster
9:00AM-11:00AM
Abstract Number: 159
The Use of “Fibromyalgia Rapid Screening Tool” for Detection of Fibromyalgia in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I
9:00AM-11:00AM
Abstract Number: 257
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Imaging of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 279
the Usefulness of Cytomegalovirus Infection Strategy in Patients with Connective-Tissue Disease, Based on the Guidelines of the Japan Society for Hematopoietic Cell Transplantation 2011
Infection-related Rheumatic Disease Poster
9:00AM-11:00AM
Abstract Number: 693
The Utility of a Rise in Anti – Double Stranded DNA Antibodies for Predicting Disease Flares in Systemic Lupus Erythematosus. a Meta-Analysis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 577
The Value of C-Reactive Protein As a Predictor of Radiographic Spinal Progression Is Strongly Dependent on β-Fibrinogen and Factor XIII a-Subunit Genotypes in Patients with Axial Spondyloarthritis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I
9:00AM-11:00AM
Abstract Number: 282
The Value of Imaging As an Early Noninvasive Test for Prosthetic Joint Septic Arthritis
Infection-related Rheumatic Disease Poster
  • «Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology